One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.
NEW YORK – Alentis Therapeutics on Tuesday announced that it has raised $181.4 million in a series D financing round, and that it will put the funds toward developing antibody-drug conjugates ...
A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.
The firm will use the funding to support the Phase I trial of its CAR T-cell therapy, VIPER-101, in lymphoma patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback